ALLOVIR-AVM-003-HC
Protocols
ADICET-ADI-001-BCELL Phase I OPEN TO ACCRUAL
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
ADP-0000-001-SCR Phase N/A OPEN TO ACCRUAL
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
ADP-0044-002-SPEARHEAD-1 Phase II OPEN TO ACCRUAL
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
ADP-0055-001-MAGE-A4-SURPASS Phase I OPEN TO ACCRUAL
A Phase 1 dose escalation study to assess safety and efficacy of ADP-A2M4CD8 as monotherapy or in combination with Nivolumab in HLA-A2+ subjects with MAGE-A4 positive tumors
ALLOGENE-ALLO-715-101-RRMM Phase I OPEN TO ACCRUAL
A Single-arm, Open-label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BMCA Allogeneic CAR T Cell Therapy with or without Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
ALLOVIR-P-106-001-RESP Phase I/II OPEN TO ACCRUAL *
Phase 1-2, double-Blind, Placebo-controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to standard of Care for the Treatment of High-Risk patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
ARCELLX-ACLX-001-DDBCMA Phase I OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-term Safety Follow-up
CARSGEN-CT041-ST-02 Phase I OPEN TO ACCRUAL *
Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
CARSGEN-CT053-MM-02 Phase I/II OPEN TO ACCRUAL
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
CELGENE-GC-LTFU-001 Phase N/A OPEN TO ACCRUAL
Long-Term Follow-up Protocol for Subjects treated with Gene-Modified T Cells
FATE-FT576-101-MM Phase I OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
GSK-3377794-LTFU Phase N/A OPEN TO ACCRUAL
Long Term Follow-Up of Participants Exposed to GSK3377794 (NY- ESO-1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
IIT-SHAH-IL7-IL15-CD20-19 Phase I/II OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
INCYTE-INCB-39110-211-CRS Phase II OPEN TO ACCRUAL
A Phase II, Single-Arm, Open-label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome (CRS) Induced by Immune Effector Cell Therapy
JNJ-68284528MMY2005-OOS Phase II OPEN TO ACCRUAL *
A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients with MM
JNJ-MY4002-CARTINUE-LTFU Phase N/A OPEN TO ACCRUAL
Long-term Follow-up Study of Participants Previously Treated with Ciltacabtagene Autoleucel
JUNO-017004-TRANSCEND-CLL Phase I/II OPEN TO ACCRUAL
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)